Jan
24
12:00 PM12:00

Mature Chamber Specific Human Cardiomyocytes for High Throughput Cardiotoxicity Testing

Human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) can be generated in nearly unlimited quantities. hiPSC-CMs have been validated for use in drug discovery projects and are replacing the use of animals in many instances. However, limitations of this in vitro system have hindered widespread adoption of hiPSC-CMs for pre-clinical toxicity testing. One limitation is the immature phenotype of hiPSC-CMs. Here we present a human cell derived extracellular matrix (ECM) plating technology that solves this limitation by promoting the maturation of hiPSC-CMs in one week. This ECM is available commercially as CELLvo™ Matrix Plus from StemBioSys. Another limitation is the lack of chamber specificity of hiPSC-CMs. Here we present data showing the impact of using chamber specific hiPSC-CMs on the outcome of medication screening. We also introduce a new commercially available atrial specific hiPSC-CM product available from StemBioSys.

Thank you to our hosts at Reprocell.

View the recording now.

View Event →
Webinar: Cell-Derived Extracellular Matrices Drive Biologically Relevant Phenotypes in Monolayer Culture and an Introduction to CELLvo™ iPS- Atrial Cardiomyocytes for in vitro Cardiotoxicity Screening
Sep
28
9:00 AM09:00

Webinar: Cell-Derived Extracellular Matrices Drive Biologically Relevant Phenotypes in Monolayer Culture and an Introduction to CELLvo™ iPS- Atrial Cardiomyocytes for in vitro Cardiotoxicity Screening

Immature phenotypes of iPSC-cardiomyocytes represent a major limitation to the productivity of human cell-based assays for cardiotoxicity. In this webinar, Drs. Block and Herron will describe CELLvo™ Matrix Plus. A human cell-derived extracellular matrix substrate that rapidly matures cardiomyocytes in monolayer culture for predictive cardiotoxicity assays. Further, they will introduce CELLvo™ iPSC-derived atrial cardiomyocytes. By utilizing chamber specific cardiomyocytes, StemBioSys has introduced a new layer of nuance and biological-relevance to in vitro testing.

Presenters: Drs. Travis Block and Todd Herron

Listen to the recording now.

If you attended the event and have questions, feel free to email us here.

View Event →
International Society for Stem Cell Research 2023 (ISSCR)
Jun
14
to Jun 16

International Society for Stem Cell Research 2023 (ISSCR)

StemBioSys Booth #317 Boston Convention and Exhibition Center

Come visit us in the Exhibit Hall to learn more about our cell-derived CELLvo™ Matrices and CELLvo™ Cells. We are happy to help guide you in your experimental design.

June 15, 2023 1:45-2 Micro Theater Talk

Cell-Derived Extracellular Matrices Drive Biologically Relevant Phenotypes in Monolayer Culture

presented by Dr. Travis Block

Ask about free samples and our exciting new product launch!!!

View Event →
Free Webinar: High Throughput Cardiotoxicity Screening Using Mature hiPSC-Cardiomyocytes (hiPSC-CMs)
May
10
10:00 AM10:00

Free Webinar: High Throughput Cardiotoxicity Screening Using Mature hiPSC-Cardiomyocytes (hiPSC-CMs)

Topic: The FDA is now accepting In Vitro cardiotoxicity screening results from human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) for investigational new drugs. Mature hiPSC-CMs are preferred in order to translate in vitro results to the adult human heart. Here we will review the use of StemBioSys’ human cell-derived extracellular matrix (ECM) CELLvo™ Matrix Plus for rapid and robust hiPSC-CM maturation using high throughput screening plates (96 well). Additionally, we will review the use of mature hiPSC-CMs for repeated measures of electrophysiological function via genetically encoded calcium indicator (GCaMP6). Repeated measures enable the ability to test the chronic effects of drugs on hiPSC-CM structure and function. Some medications can cause delayed onset toxicity that can only be measured in vitro using repeated measures. Data shows the utility of mature hiPSC-CM in vitro assays to determine toxicity occurring over the course of four days with measurements of intracellular calcium flux and monolayer confluence.         

 

Presenters: Travis Block and Todd Herron.

 Email us at info@stembiosys.com for more information.

View Event →
Mar
19
9:00 AM09:00

Society of Toxicology 2023- Nashville, Tennessee

StemBioSys will be exhibiting and participating in an Exhibitor Hosted Session at SOT 2023.

Come See us at Booth 1426 for free samples.

Exhibitor Hosted Session: Cell-derived extracellular matrices for high throughput screening of PSC-derived somatic cells with mature, biologically-relevant phenotypes.

Date: March 21, 2023

Time: 9 AM- 10 AM

Room Assignment 101D

View Event →
Safety Pharmacology Society 2020 Virtual Meeting
Sep
14
to Sep 17

Safety Pharmacology Society 2020 Virtual Meeting

2020 — Virtual • September 14 to 17

September 14–17—Scientific Sessions, Virtual Posters, Virtual Exhibit Hall, and more!
Coming soon—CE Course Schedule

Sign up below to Preregister for the Sponsored Presentation :

Title: Extracellular Matrix and hiPSC derived cardiomyocytes – solving the maturation problem

Speakers: Travis Block, PhD (StemBioSys) and Todd Herron, PhD (University of Michigan and Cartox)

Topic: While, in theory, iPSCs can differentiate into any cell type in the body, there are important differences between iPSC-derived cell types and those found in somatic tissues.  These differences are troubling for drug and toxicity screening applications, because nuances in gene expression that are seemingly minor may impact cell responses.  Here we describe the development and application of a cell-derived extracellular matrix for the rapid maturation of cardiomyocytes in monolayer culture.

View Event →
2020 TERMIS EU-Chapter/Manchester - Postponed to 2023
May
26
to May 29
Events

2020 TERMIS EU-Chapter/Manchester - Postponed to 2023

  • Manchester Central Convention Complex (map)
  • Google Calendar ICS

Join us at Stand 22 during the Tissue Engineering and Regenerative Medicine International Society (TERMIS) European Chapter Meeting. We will be with our distributor, Caltag Medsystems. TERMIS is the leading event for the dissemination of the latest research in tissue engineering and regenerative medicine, offering researchers, clinicians and industry an ideal opportunity to present and discuss their most recent findings, developments and challenges in the field.

View Event →